NASDAQ:GILDGilead Sciences Stock Price, Forecast & News

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GILD shares have increased by 3.2% and is now trading at $76.06. View which stocks have been most impacted by Coronavirus.

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 3 sell ratings, 15 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Gilead Sciences.

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Gilead Sciences.

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings data on Thursday, April, 30th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.11. The biopharmaceutical company earned $5.55 billion during the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The business's revenue for the quarter was up 5.1% on a year-over-year basis. During the same period last year, the company earned $1.67 earnings per share. View Gilead Sciences' earnings history.

Gilead Sciences announced a quarterly dividend on Thursday, April 30th. Stockholders of record on Friday, June 12th will be paid a dividend of $0.68 per share on Monday, June 29th. This represents a $2.72 dividend on an annualized basis and a yield of 3.58%. The ex-dividend date of this dividend is Thursday, June 11th. View Gilead Sciences' dividend history.

28 equities research analysts have issued 1-year price objectives for Gilead Sciences' stock. Their forecasts range from $60.00 to $97.00. On average, they expect Gilead Sciences' stock price to reach $79.65 in the next twelve months. This suggests a possible upside of 4.7% from the stock's current price. View analysts' price targets for Gilead Sciences.

Media headlines about GILD stock have trended very negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gilead Sciences earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Gilead Sciences.

Gilead Sciences saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 24,140,000 shares, a drop of 7.5% from the May 31st total of 26,090,000 shares. Based on an average daily trading volume, of 21,470,000 shares, the days-to-cover ratio is currently 1.1 days. Approximately 1.9% of the shares of the company are sold short. View Gilead Sciences' Current Options Chain.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include Walt Disney (DIS), Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Intel (INTC), Micron Technology (MU), AbbVie (ABBV), Johnson & Johnson (JNJ), AT&T (T) and Tesla (tsla).

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Confluence Investment Management LLC (0.10%), Thomasville National Bank (0.01%) and Modus Advisors LLC (0.00%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John C Martin, John Francis Cogan, Olsen Per Wold and Richard James Whitley. View institutional ownership trends for Gilead Sciences.

GILD stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, and Olsen Per Wold. View insider buying and selling activity for Gilead Sciences.

GILD stock was purchased by a variety of institutional investors in the last quarter, including Thomasville National Bank, and Modus Advisors LLC. View insider buying and selling activity for Gilead Sciences.

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GILD stock can currently be purchased for approximately $76.06.

Gilead Sciences has a market capitalization of $95.41 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis. Gilead Sciences employs 11,800 workers across the globe.

The official website for Gilead Sciences is www.gilead.com.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]